
Accuray (ARAY) Stock Forecast & Price Target
Accuray (ARAY) Analyst Ratings
Bulls say
Accuray is facing challenges from geopolitical uncertainty and a history of lumpy reporting quarters and age-outs, however the company's recent acquisition of TomoTherapy and its innovative technology, CyberKnife, provide potential for growth. Despite lower forecasted revenue and margins, Accuray has potential for operating improvements and commercial execution.
Bears say
Accuray is struggling with geopolitical tensions in the Middle East and headwinds in China, leading to a decline in product revenue and lowered guidance for FY26. Although the company's transformation plan is underway and they have improved investor sentiment, the lack of progress on commercial execution and profitability metrics is a concern. The company also faces risks such as potential tariffs, supply chain challenges, and geopolitical tensions, which may further hinder their performance.
This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.
Accuray (ARAY) Analyst Forecast & Price Prediction
Start investing in Accuray (ARAY)
Order type
Buy in
Order amount
Est. shares
0 shares